Evaluation of clinical pharmacological effects of atorvastatin combined with trimetazidine in the treatment of coronary heart disease
阿托伐他汀联合曲美他嗪治疗冠心病临床药学效果评价

摘要

目的 对于接受治疗的冠心病患者，在治疗中应用曲美他嗪和阿托伐他汀相联合的方式进行治疗，观察临床效果，使得患者的心功能水平以及炎性因子水平被有效改善，为此类患者的临床治疗提供参考依据。方法 将2021年2月至2022年2月在我院门诊接受治疗的冠心病患者作为此次研究实验的对象，共选取300例，按照患者治疗方式的差异进行分组，两组患者的人数均等，分别为患者实施常规治疗法和曲美他嗪联合阿托伐他汀治疗法，观察两组患者的效果差异。结果 （1）两组患者接受不同的治疗方式之后的临床效果存在明显的差异，而研究组患者中治疗效果高达97.00%，远远优于对照组患者（p＜0.05）；（2）研究组患者的各项炎性因子水平均更低（p＜0.05）；（3）患者在接受治疗之后的各项心功能水平均比较优异，其中LVESD水平以及LVEDD水平低于对照组，而LVEF水平高于对照组，两组患者的数据差异在统计学方面存在统计意义（p＜0.05）。结论 接受门诊治疗的冠心病患者，在治疗期间使用曲美他嗪和阿托伐他汀相联合的方式进行治疗可以有效改善患者的心功能水平，有效地降低患者的各项炎性因子水平，因此患者的临床疗效也更加优异，值得推广。

Abstract

Objective For patients with coronary heart disease receiving treatment, the combination of trimetazidine and atorvastatin was used for treatment, and the clinical effect was observed, so that the cardiac function level and inflammatory factor level of the patients were effectively improved , to provide a reference for the clinical treatment of such patients.
Methods A total of 300 patients with coronary heart disease who were treated in the outpatient department of our hospital from February 2021 to February 2022 were selected as the subjects of this research experiment. They were divided into groups according to the differences in the treatment methods of the patients. The patients were treated with conventional therapy and trimetazidine combined with atorvastatin therapy, respectively, and the differences in the effects of the two groups were observed.
Results (1) There were significant differences in the clinical effects of the two groups of patients after receiving different treatment methods, and the treatment effect in the study group was as high as 97.00%, which was much better than that in the control group (p<0.05); (2) The study group The levels of various inflammatory factors in the patients were lower (p<0.05); (3) the cardiac function levels of the patients after receiving treatment were all better, among which the levels of LVESD and LVEDD were lower than those of the control group, while the level of LVEF was higher In the control group, the data difference between the two groups was statistically significant (p < 0.05).
Conclusion   In patients with coronary heart disease receiving outpatient treatment, the combination of trimetazidine and atorvastatin during treatment can effectively improve the patient's cardiac function level and effectively reduce the level of various inflammatory factors. The clinical efficacy of patients is also more excellent, which is worthy of promotion.